文献速递细菌感染、耐药与抗菌药物

从关联到因果:用因果机器学习评估既往抗生素暴露与耐药性

Progressing From Association to Causation: Examining Prior Antibiotic Exposure and Antimicrobial Resistance Across Three US Health Systems Using Causal Machine Learning.
PubMed 文献 · Clin Infect Dis · 2026-10-15

该研究分析美国3个医疗系统1 165 151例培养 episod,采用双机器学习调整每中心超35个混杂因素,估计90天内既往暴露与同类抗生素不敏感性的因果效应。既往氟喹诺酮暴露使不敏感性增加8.6–12.6个百分点,7类抗生素均见正相关,提示经验性治疗失活率更高。

要点

  • 既往同类抗生素暴露与后续同类不敏感性增加相关,因果推断框架支持该关联。
  • 氟喹诺酮暴露后不敏感性增加8.6–12.6个百分点,30天效应最强,365天衰减。
  • 有氟喹诺酮暴露者经验性治疗失活率50%–71%,无暴露者27%–37%。

核心结论

  • 既往抗生素暴露与同类不敏感性增加一致相关,跨7类抗生素和3个医疗系统。
  • 该关联伴随更高的微生物学失活经验性治疗率,支持前瞻性评估基于抗生素史的经验性处方。

研究设计与样本

  • 分析Mass General Brigham、Stanford Health Care和Beth Israel Deaconess Medical Center(经MIMIC-IV)共1 165 151例培养 episod。
  • 采用双机器学习估计90天既往暴露对同类耐药的因果效应,每中心调整超35个混杂因素。
  • 通过逆概率加权、E值、暴露窗口和剂量反应敏感性分析及阴性对照对进行稳健性评估。

主要发现

  • 既往氟喹诺酮暴露使不敏感性增加:主要中心(MGB、Stanford)11.9和12.6个百分点,验证中心(BIDMC)8.6个百分点(均P < .001)。
  • 所有7类抗生素在所有中心均见正相关(Stanford磺胺类不确定),30天最强,至365天衰减。
  • 有氟喹诺酮暴露且接受氟喹诺酮经验性治疗的血流感染中,50%–71%治疗失活,无暴露者为27%–37%。
  • 跨类别共3309例失活经验性处方与既往同类暴露相关。
  • 中位E值为2.5。

临床怎么用

  • 经验性处方前应考虑患者既往抗生素暴露史,尤其90天内同类药物使用。
  • 对既往氟喹诺酮暴露者,经验性使用氟喹诺酮需警惕高失活风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotic exposure is hypothesized to drive antimicrobial resistance, but confounding by indication has limited causal inference from observational data. We estimated the effect of prior exposure on subsequent same-class nonsusceptibility across 7 antibiotic classes and 3 US health systems using a causal-inference framework. METHODS: We analyzed 1 165 151 culture episodes from Mass General Brigham (MGB), Stanford Health Care, and Beth Israel Deaconess Medical Center (BIDMC; via MIMIC-IV). The causal effect of 90-day prior exposure on same-class resistance was estimated by double machine learning, adjusting for more than 35 confounders per site, including prior same-class resistant isolates, infecting-organism group, and calendar period. Robustness was assessed via inverse probability weighting, E-values, exposure-window and dose-response sensitivity, and negative-control pairs. Rates of microbiologically inactive empiric therapy were compared by prior same-class exposure. RESULTS: Prior fluoroquinolone exposure was associated with increased nonsusceptibility by 11.9 and 12.6 percentage points at the primary sites (MGB, Stanford) and 8.6 points in validation (BIDMC) (all P < .001). Positive associations occurred for all 7 classes at all sites (sulfonamides indeterminate at Stanford), strongest at 30 days and attenuating through 365 days. Among patients with prior fluoroquinolone exposure receiving empiric fluoroquinolones for bloodstream infection, therapy was inactive in 50%-71% of episodes versus 27%-37% without prior exposure. Across classes, 3309 inactive empiric prescriptions were associated with prior same-class exposure. Median E-value was 2.5. CONCLUSIONS: Prior antibiotic exposure was consistently associated with increased same-class nonsusceptibility across antibiotic classes and health systems, paralleling higher rates of microbiologically inactive empiric therapy. These findings support prospective evaluation of antibiotic-history-informed empiric prescribing.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kuruvikkattil AV, Shukla S, Celi LA, et al. Progressing From Association to Causation: Examining Prior Antibiotic Exposure and Antimicrobial Resistance Across Three US Health Systems Using Causal Machine Learning. Clin Infect Dis. 2026. PMID: 42878671. doi:10.1093/cid/ciag549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。